News from Monday, May 19, 2025
Articles
Value Viewpoint: May 16, 2025
(5/16, Kimberly Westrich, LinkedIn) comments “Two new studies from NPC, published this week in Value in Health, underscore the importance of incorporating dynamic pricing and other evolving inputs into cost-effectiveness analyses (CEAs) to more accurately represent the value of prescription drugs across their lifecycles.” Full
Understanding What Recent Court Action Means to 340B Reform
(5/19, Dinesh Kabaleeswaran, AJMC) reports “...A study by the National Pharmaceutical Council, appearing in the journal Inquiry, found that participants made the most money off 340B from drugs prescribed in wealthy areas.” Full
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
(5/17, AJMC) reports “...‘By utilizing a large population-level dataset, our study showed that acalabrutinib produces less [atrial fibrillation] and [hypertension] compared to ibrutinib; in doing so, it confirms the findings of the ELEVATE-RR trial in a real-world setting,’ the researchers wrote.” Full
Press Releases
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
(5/19, aTyr Pharma) “...‘New real-world evidence underscores the growing burden of patients living with pulmonary sarcoidosis and the continued reliance on oral corticosteroids as the standard of care, despite their limited clinical evidence and toxic side effects. These findings highlight a clear and urgent need for safer, more effective treatments for patients with this chronic disease,’ said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.” Full
Journals
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
Yewande Odeyemi, et al.
May 16, 2025, Clinical Infectious Diseases
Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study
A. Marco-Rico, et al.
May 19, 2025, Journal of Blood Medicine
Reports
HTA Review Implementation Advisory Group Communique – Framework for Recommendation Analysis
May 16, 2025